ReviewFrontiers in immunology2026
Advances in immunotherapy for renal cell carcinoma: a comprehensive review.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review examines the evolving first-line immunotherapy landscape in metastatic renal cell carcinoma (mRCC), with emphasis on the comparative clinical logic of dual immune checkpoint blockade (ICI-ICI) and immune checkpoint inhibitor-tyrosine kinase inhibitor combinations (ICI-TKI), the persistent efficacy-effectiveness gap, biomarker development, and translational resistance biology. Pivotal phase III trials have established superior survival for contemporary ICI-based regimens over sunitinib; however, cross-trial heterogeneity, differences in IMDC risk distribution, varying toxicity profiles, and selection of fitter trial populations complicate simple regimen ranking. Real-world studies confirm that outcomes in routine practice are frequently less favorable than those reported in registration studies, but these differences are partly explained by confounding related to performance status, comorbidity burden, access to care, toxicity management, and treatment sequencing. Renal cell carcinoma remains a biomarker-challenged disease in which PD-L1 and tumor mutational burden have limited predictive value, while PBRM1 status, VHL-driven pseudohypoxia, and spatial immune architecture are biologically informative but not yet clinically validated as stand-alone selection tools. Resistance arises through tumor-intrinsic metabolic reprogramming, impaired antigen presentation, compensatory checkpoint signaling, and stromal-myeloid exclusion within the tumor microenvironment. Taken together, the field is moving from empirical regimen selection toward a model that integrates disease tempo, patient fitness, translational biomarkers, and mechanism-based sequencing. Future progress will depend on composite biomarker validation, biomarker-enriched trials, rational resistance-directed combinations, and structural measures that improve external validity and equitable access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.